At present, due to the complexity of tumor immune microenvironment(TME), the existence of tumor immune evasion, and the ununified laboratory detection technology, PD-L1 detection alone cannot find all patients with cancer who benefit from immunotherapy (9, 10). Here, CD274 is linked to neoplasm.